Drug intelligence / Profile preview

Niféxine

Development stage: Unknown
Lead developer: Laboratoires Leurquin Mediolanum
Modality: Small Molecules
Administration: Rectal, Topical

Overview

**Niféxine** is a French prescription fixed-dose rectal cream containing nifedipine 0.3% and lidocaine hydrochloride 1.5%, indicated in adults for relief of pain associated with chronic anal fissure after usual treatment for acute fissure symptoms has failed. Nifedipine, a dihydropyridine calcium-channel blocker, relaxes the internal anal sphincter and improves local blood flow; lidocaine is an amide local anesthetic that provides rapid local analgesia through sodium-channel blockade. ([leurquin-mediolanum.fr](https://leurquin-mediolanum.fr/m%C3%A9dicaments/nifexine/))

Brand names: Niféxine
Other names: nifedipine + lidocaine hydrochloride

Targets

CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on Niféxine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Niféxine.

Explore the full profile